Skip to main content
All lobbying filings

Alston & Bird LLP

Alston & Bird LLP filed a Q3 report for Biomerieux, Inc. on October 20, 2025, reporting $70,000 in lobbying income.

Lobbying for Biomerieux, Inc. · Global in vitro diagnostics company.

As filed: ALSTON & BIRD LLP for BIOMERIEUX, INC.

All filings by Alston & Bird LLP · Everything Biomerieux, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$70,000
What the client paid this registrant for the period.
Client based in
Utah

Official filing document

 Lobbyists on this filing 1
  • MICHAEL PARK New on this filing
    Previously held: Health Policy Counsel, Senate Finance Committee.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Budget/Appropriations

Pub. L. No. 119-21, One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics.

Health Issues

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). Reforming technical certification of in vitro diagnostic tests.

Medical/Disease Research/Clinical Labs

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). Reforming technical certification of in vitro diagnostic tests.

Medicare/Medicaid

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)). H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.

Trade (domestic/foreign)

Discussions regarding tariff proposals.

Taxation/Internal Revenue Code

Pub. L. No. 119-21, One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of U.S. Tax Code.

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem